# HEM1036 Phase 2 Study in Low Anterior Resection Syndrome

> **NCT05527301** · PHASE2 · UNKNOWN · sponsor: **HEM Pharma Inc.** · enrollment: 67 (estimated)

## Conditions studied

- LARS - Low Anterior Resection Syndrome

## Interventions

- **DRUG:** Lactobacillus Fermentum
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05527301
- **Lead sponsor:** HEM Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2023-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05527301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05527301, "HEM1036 Phase 2 Study in Low Anterior Resection Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05527301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*